Antibody engineering for therapeutics.
With the acceptance of antibodies as therapeutics, a diversity of engineered antibody forms have been created to improve their efficacy, including enhancing the effector functions of full-length antibodies, delivering toxins to kill cells or cytokines in order to stimulate the immune system, and bispecific antibodies to target multiple receptors. After years of in vitro investigation, many of these are now moving into clinical trials and are showing promise. A potential new type of effector function for antibodies, that is, the generation of reactive oxygen species that may effect inflammation or bacterial killing, has been elucidated. In addition, the field has expanded beyond a concentration on immunoglobulin G to include immunoglobulin A antibodies as potential therapeutics.
Presta
Leonard
L
Department of Protein and Antibody Technology, DNAX Inc, 901 California Avenue, Palo Alto, CA 94304-1104, USA. leonard.presta@dnax.org
D000818:Animals; D000906:Antibodies / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D016207:Cytokines / Q000235:genetics / Q000494:pharmacology*; D006801:Humans; D000922:Immunotoxins / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D015202:Protein Engineering; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000494:pharmacology
D000906:Antibodies; D016207:Cytokines; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins